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pharmacological inhibition of 
ataxia-telangiectasia mutated 
exacerbates acute kidney injury by 
activating p53 signaling in mice
Masahiro Uehara  1, tetsuro Kusaba1*, tomoharu ida1, Kunihiro nakai1, tomohiro nakata1, 
Aya tomita1, noriko Watanabe-Uehara1, Kisho ikeda1, takashi Kitani1, noriyuki Yamashita1, 
Yuhei Kirita  1,3, Satoaki Matoba2, Benjamin D. Humphreys3 & Keiichi tamagaki  1
the DnA damage response after kidney injury induces cell cycle arrest in renal tubular epithelial 
cells, resulting in the secretion of pro-fibrotic cytokines, thereby promoting interstitial fibrosis in a 
paracrine manner. phosphorylation of ataxia-telangiectasia mutated (AtM) is the initial step in the 
DNA damage response and subsequent cell cycle arrest; however, the effects of ATM inhibition on the 
injured kidney have not been explored. Pharmacological ATM inhibition by KU55933 in cisplatin-treated 
mice did not ameliorate, but instead exacerbated cisplatin-induced DnA damage and tubular injury, 
thereby increasing mortality. Analysis of isolated tubular epithelia by FACS from bigenic SLC34a1-
CreERt2; R26tdTomato proximal tubular-specific reporter mice revealed that KU55933 upregulated 
p53 and subsequent pro-apoptotic signaling in tubular epithelia of cisplatin-treated mice, leading 
to marked mitochondrial injury and apoptosis. In addition, KU55933 attenuated several DNA repair 
processes after cisplatin treatment, including single-strand DnA repair and fanconi anemia pathways, 
suggesting that DNA repair after dual treatment of cisplatin and KU55933 was not sufficient to prevent 
the cisplatin-induced tubular injury. our study suggested that AtM inhibition does not increase DnA 
repair after cisplatin-induced DnA damage and exacerbates tubular injury through the upregulation 
of p53-dependent pro-apoptotic signaling. Acute kidney injury must be carefully monitored when ATM 
inhibitors become available in clinical practice in the future.
Society is aging worldwide, and the number of patients with end-stage organ failure involving the heart, lung, 
and kidney, and the costs of treating these diseases are increasing1. Recent epidemiological investigations demon-
strated that a past history of acute kidney injury (AKI) is a strong determinant of the future incidence of CKD2–4. 
Maladaptive tubular repair after AKI is one of the underlying mechanisms for this process, eventually leading to 
tissue fibrosis and the subsequent loss of kidney function5,6.
Numerous insults, such as anticancer drugs and hemodynamic abnormalities, are known causes of AKI7. 
Cisplatin is a platinum-based anticancer drug that is widely used to treat many types of cancer, but the main 
dose-limiting side effect of cisplatin is nephrotoxicity8,9. Circulating cisplatin is transported into proximal tubular 
epithelia through the organic cation transporter 2 (OCT2), which is highly expressed in the basolateral mem-
brane10. The accumulated cisplatin directly binds to DNA, which inhibits transcription and DNA replication, 
thereby inducing cell death11,12. For cell survival after injury, complex signaling pathways, known as the DNA 
damage response (DDR), are activated in the injured cells, and the detection and repair of DNA damage by 
transient cell cycle arrest are orchestrated to ensure the maintenance of genomic stability or integrity. In DDR, 
ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia and Rad3-related (ATR), which are members of 
the phosphatidylinositol 3 kinase-related kinase (PIKK) family, play central roles in the activation of cell cycle 
arrest and cell death in the case of severe DNA damage.
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Regarding the impact of cell cycle arrest on the development of CKD after injury, the downstream signaling 
of ATM, such as p53 in the injured tubular epithelia, is controversial. Sustained G2/M arrested tubular epithelia 
after kidney injury in vivo resulted in kidney fibrosis via upregulation of the production of profibrotic cytokines 
like TGFβ and CTGF13,14. ATM inhibition in vitro inhibited cell cycle arrest after aristrochiac acid treatment and 
ameliorated the profibrotic gene upregulation. In addition, p53, a major downstream molecule of ATM, plays an 
essential role in apoptosis induction after injury, and the inhibition of p53 ameliorated kidney injury in vivo13,15–19. 
In contrast, Ma et al. reported that p53 inhibition exacerbated the tubular apoptosis induced by ischemia reper-
fusion injury20.
ATM inhibitors are emerging as candidate cancer therapeutics based on their effects on the increased hyper-
sensitivity to irradiation of ATM-deficient cells21–24. In pre-clinical trials, transient inhibition of ATM led to radi-
osensitization or chemosensitization in vivo and in vitro25–27, thus it is possible that ATM inhibitors strengthen 
the effects of anti-cancer drugs or irradiation. For other disease conditions, genetic ATM deletion ameliorated 
doxorubicin-induced cardiotoxicity28 and pressure overload-induced heart failure29.
Considering these previous studies, whether inhibition of ATM and its downstream signaling exert renopro-
tective effects after injury is unclear. To address this controversy, we administered KU55933, a selective ATM 
inhibitor27, to mice with cisplatin-induced AKI. We found that marked tubular injury developed after combina-
tion treatment with cisplatin and ATM inhibitor, leading to a higher mortality rate. Analysis of isolated proximal 
tubular epithelia demonstrated p53 upregulation despite ATM inhibition during injury. These results suggest that 
the nephrotoxicity of cisplatin is exacerbated by ATM inhibition, and AKI must be carefully monitored when 
these therapies become available in clinical practice in the future.
Results
AtM inhibition increases the mortality of cisplatin-induced nephrotoxicity. In order to inves-
tigate whether ATM inhibition can ameliorate kidney fibrosis at the chronic phase of cisplatin nephropathy, we 
injected KU55933 into mice that received cisplatin at the indicated time points (Fig. 1a). Co-administration of 
KU55933 and cisplatin significantly increased mortality (Fig. 1b). The BUN was significantly increased in the 
cisplatin-injected mice, and this increase was marked in the mice that received KU55933 and cisplatin (Fig. 1c). 
The kidneys of these mice exhibited extensive tubular injury characterized by detachment of tubular epithelia 
from the basement membrane and tubular cast formation (Fig. 1d,e), whereas KU55933 treatment alone did not 
induce morphological changes in the kidney (Supplementary Fig S1). Of note, numerous tubules with denuded 
tubular basement membrane where the tubular epithelia had completely detached were observed in the kidneys 
of mice that received KU55933 and cisplatin.
AtM inhibition accelerates cisplatin-induced tubular injury. To investigate the detailed morpholog-
ical phenotypes, we assessed the expression of kim-1, a marker of tubular injury, and megalin, a marker of mature 
tubular epithelia. Immunostaining for kim-1 demonstrated a large number of positive tubules in the kidney of 
the mice that received cisplatin alone, whereas staining was much weaker in those that received KU55933 and 
cisplatin (Fig. 2a). In contrast, immunostaining for megalin was weak in the kidneys of the mice that received 
cisplatin with or without KU55933 (Fig. 2a). Of note, due to the complete detachment of tubular epithelia, tubules 
with denuded tubular basement membrane were negative for both megalin and kim-1, reflecting severe tubular 
injury (Supplementary Fig S2).
qPCR of whole kidney RNA confirmed the decreased expression of the mature tubular epithelia markers 
slc34a1 and lrp2 (encoding megalin) in cisplatin-injected mice, which was significantly lower in the mice that 
received KU55933 and cisplatin. Havcr1 (encoding Kim-1) expression was upregulated in cisplatin-treated mice, 
and there was no difference between the mice with or without co-administration of KU55933. However, upreg-
ulation of another tubular injury marker, lcn2 (encoding Ngal), was marked in the kidneys of the mice that 
received KU55933 and cisplatin. Profibrotic cytokines, ccn2 and tgfb1, and inflammation markers, cd68 and tnf, 
were upregulated in cisplatin-treated mice, and this upregulation was slightly higher in the mice that received 
KU55933 and cisplatin (Fig. 2b).
AtM inhibition accelerates DnA damage in tubular epithelia. As most of the severely injured 
tubular epithelia were lost due to substantial detachment from the tubular basement membrane 4 days after 
KU55933 and cisplatin treatment, we further analyzed the phenotypes at an earlier phase of 2 days after treat-
ment. In addition, for tubular epithelia-specific analysis, we used bigenic mice with a proximal tubule-specific 
tamoxifen-inducible Cre (SLC34a1GCE) and the tdTomato reporter (R26tdTomato), in which proximal tubules 
were exclusively labeled by tdTomato after tamoxifen injection30. After labeling the proximal tubular epithelia by 
tamoxifen, the mice were used for experiments (Fig. 3a). Western blotting of whole kidney lysates revealed that 
KU55933 downregulated pATM expression in cisplatin-treated mouse kidneys (Fig. 3b,c). On immunohisto-
chemistry of pATM, cisplatin increased the amount of nuclear pATM+ tubular epithelia, whereas it was signifi-
cantly reduced by KU55933 (Fig. 3d,e). Regarding the specific expression of pATM in proximal tubular epithelia, 
immunostaining of pATM revealed that KU55933 significantly reduced the amount of pATM+ tdTomato+ 
tubular epithelia (Supplementary Fig S3a, S3b). Based on PAS staining, cisplatin-treated mice had tubular injury 
that was more severe in those that also received KU55933 (Fig. 3f,g). However, observation of detached tubular 
epithelia 4 days after treatment (Fig. 1d) was rare even in the mice that received both KU55933 and cisplatin. 
Based on immunostaining of KIM-1, the number of KIM-1+ cells was higher in mice that received KU55933 and 
cisplatin (Fig. 3h,i). To evaluate DNA damage as a consequence of cisplatin administration, we performed immu-
nostaining of γH2AX. In both cisplatin-treated mice kidneys, a large number of γH2AX+ tubular epithelia were 
found, and this proportion was higher in the mice that received both KU55933 and cisplatin (Fig. 3j,k). In order 
to confirm the additional adverse effects of KU55933 on cisplatin-induced DNA damage and to elucidate the 
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Figure 1. ATM inhibition increases the mortality rate and exacerbates tubular injury in cisplatin nephropathy. 
(a) Experimental scheme. Mice received intraperitoneal injections of cisplatin (15 mg/kg), KU55933 (5 mg/
kg), or vehicle as indicated. (b) Kaplan-Meier curve for animal survival. KU55933 increased the mortality 
of cisplatin nephropathy. p = 0.0103 by the log rank test. n = 10 per group. (c) BUN increase in cisplatin 
nephropathy was accelerated by KU55933. n = 4–5 per group. (d) PAS staining of kidney sections (4 days after 
treatment) and (e) quantification of tubular injury score. Asterisks indicate the denuded tubular basement 
membrane. For all groups, data are means ± SEM, *p < 0.05 vs control, #p < 0.05 vs cisplatin, Bar = 1 mm in 
low-power field pictures and = 50 μm in high-power field pictures in (d).
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type of DNA damage in the kidney, we performed comet assay of isolated kidney cells from the mice 2 days after 
treatment. The comet tail moment in the alkaline condition (alkaline comet) reflects both DNA double stranded 
breaks (DSB) and single stranded breaks (SSB), whereas that in the neutral condition (neutral comet) reflects 
only DNA DSB31. We found that alkaline comet tail moments were increased in kidney cells from cisplatin treated 
mice, and were further increased in cells from both cisplatin- and KU55933-treated mice (Fig. 3l,m). Neutral 
comet tail moments were also increased in kidney cells from cisplatin-treated mice, and were further increased 
in those from both cisplatin- and KU55933-treated mice; however, the difference between the two groups was 
less for neutral comet tail moments (Fig. 3l,n). This suggests that DNA DSB and SSB occurred in the kidney after 
cisplatin administration, and that KU55933 accelerated the cisplatin-induced DNA damage, mainly DNA SSB.
Phosphorylation of ATR is another important responsive factor against DNA damage. In order to investigate 
the compensatory upregulation of ATR, immunostaining of pATR was performed. pATR+ cells were increased 
in cisplatin-treated mouse kidneys, and they were further increased in the mice that received both KU55933 and 
cisplatin (Supplementary Fig S4a, S4b).
Tubular-specific phenotypes using FACS-sorted cells. In order to specifically analyze the phenotypes 
of proximal tubular epithelia, we collected the tdTomato+ tubular epithelia by fluorescence-activated cell sorting 
Figure 2. ATM inhibition upregulated proinflammatory and profibrotic signaling in cisplatin nephropathy. 
(a) Immunostaining of kidney sections for Kim-1 and megalin (4 days after treatment). (b) qPCR of RNA from 
whole kidneys for the representative markers of mature tubules (slc34a1 and megalin), of tubular injury (kim-1 
and ngal), profibrotic cytokines (tgfb and ctgf), and inflammation (cd68 and tnfa). For all groups, data are 
means ± SEM, *p < 0.05 vs control, #p < 0.05 vs cisplatin, Bar = 100 μm in (a).
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(FACS), and RNA and protein were extracted for further analysis (Fig. 4a). qPCR of isolated tubular epithe-
lia demonstrated that RNA expression of lrp2 and slc34a1 was significantly reduced in the mice that received 
KU55933 and cisplatin (Fig. 4b). Havcr1 expression was not affected by KU55933, but the expression of vim and 
cd44, which are mesenchymal markers, was significantly upregulated in the mice that received KU55933 and 
cisplatin (Fig. 4b), suggesting that the injured tubular epithelia underwent intratubular epithelial-mesenchymal 
transition, as observed on immunofluorescence images (Supplementary Fig S5). Regarding profibrotic and 
proinflammatory cytokines, ccn2 and tgfb1 expression did not differ between cisplatin with or without KU55933 
(Fig. 4b). Regarding cell cycle markers, we evaluated the expression of regulatory molecules associated with the 
G1/S phase, including pcna and fen1, and the G2/M phase, including cdk1 and top2a32,33. Pcna and fen1 mRNA 
Figure 3. Acute effects of ATM inhibition on cisplatin nephropathy. (a) Experimental scheme. Bigenic mice 
(SLC34a1GCE x R26tdTomato) received intraperitoneal injections of cisplatin (15 mg/kg), KU55933 (5 mg/kg 
at each time point), Tamoxifen (3 mg/kg at each time point), or vehicle as indicated. (b). Western blot of protein 
lysates from whole kidneys for pATM, ATM, and GAPDH. Representative pictures of n = 2. Western blotting 
with n = 3 per group. (c) The optical density of pATM bands was normalized against that of GAPDH. (d) 
Immunostaining of kidney sections (2 days after treatment) for pATM and (e) quantification of nuclear pATM+ 
cells per low-power field picture (n = 4 per group). The small square in the WT image indicates the tubules 
with negative nuclear but high cytoplasmic staining. (f) PAS staining of kidney sections and (g) quantification 
of the tubular injury score. (h) Immunostaining of kidney sections for Kim-1 and (i) quantification of Kim-1+ 
cells per low-power field picture. (j) Immunostaining of kidney sections for γH2Ax and (k) quantification of 
γH2Ax + cells per low-power field picture. (l) Representative images of comet assay of kidney cells isolated 
from mice at 2 days after treatment and (m,n) quantitative analysis (M: alkaline comet: n = 100 each, N: neutral 
comet: n = 50 each). For all groups, data are means ± SEM, *p < 0.05 vs control, #p < 0.05 vs cisplatin, Bar = 
100 μm in (d,f,h,j).
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expression was increased in the mice that received KU55933 and cisplatin, whereas cdk1 and top2a mRNA 
expression did not differ among all groups, suggesting that most cells arrested in the G1 phase34.
ATM inhibition increased p53 expression in the tubular epithelia of cisplatin-treated mice. In 
order to explore the molecular mechanism in detail, we focused on p53 expression, which is major downstream 
signaling factor of ATM. Western blot analysis using isolated tubular epithelia by FACS demonstrated that cis-
platin induced p53 and CDK2 expression, which was not attenuated but upregulated in the mice that received 
both KU55933 and cisplatin (Fig. 5a–c). Regarding further downstream signaling of p53, qPCR using isolated 
tdTomato+ tubular epithelia confirmed the upregulation of cdkn1a (encoding p21), and bax, and bbc3 (encoding 
PUMA) in cisplatin-treated mice, which was slightly higher in the mice that also received KU55933 (Fig. 5d). 
Considering the upregulation of pro-apoptotic genes, we performed TUNEL staining to evaluate apoptotic cells. 
Figure 4. qPCR analysis of isolated proximal tubular epithelia from the mice that received cisplatin by FACS. 
(a) Isolation of tdTomato+ tubular epithelial cells using FACS as described in the experimental scheme in 
Fig. 3a. (b) qPCR of RNA from isolated tubular epithelia for the representative markers of mature tubules (lrp2), 
tubular injury (havcr1), dedifferentiation or mesenchymal markers (cd44 and vim), profibrotic cytokines (ccn2, 
tgfb1 and pdgfb), proinflammatory cytokines (tnf), and cell cycle (G1/S for pcna and fen1, G2/M for cdk1 and 
top2a). For all groups, data are means ± SEM, *p < 0.05 vs control, #p < 0.05 vs cisplatin.
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TUNEL+ cells were found in cisplatin-treated kidneys, and there were significantly more in the kidneys from 
mice treated with cisplatin and KU55933 (Fig. 5e,f). As previous studies found that cisplatin can induce mito-
chondrial injury through activation of the p53-PUMA axis8, we evaluated the expression of TOM20, a protein 
of the mitochondrial membrane. Immunostaining for TOM20 was weak in the kidneys from mice that received 
cisplatin, but it was even weaker in those of mice that received both KU55933 and cisplatin (Fig. 5g).
Figure 5. Activation of p53 signaling in proximal tubular epithelia in the cisplatin-treated mice with ATM 
inhibition. (a) Western blot of protein lysate from isolated tubular epithelia for p53, CDK2, and GAPDH. 
Representative pictures from n = 2. Western blotting with n = 4–6 in each group is shown. Optical density 
of (b) p53 and (c) CDK2 bands were normalized against those of GAPDH. The normalized density of the 
samples from the control mice was arbitrarily set to 1. (d) qPCR of RNA from isolated tubular epithelia for 
the downstream signaling of ATM and p53. (e) TUNEL staining of kidney sections (4 days after treatment) 
and (f) quantification of TUNEL + cells. (g) Immunostaining of kidney sections (4 days after treatment) for 
Tom20. (h) Kaplan-Meier curve for animal survival. Pifithrin-α slightly improved the mortality rate of cisplatin 
nephropathy after KU55933 administration. Log rank test. n = 8 in the pifithrin-α-treated group and n = 10 in 
the other group. (i) The BUN increase at 4 days after treatment did not differ between the two groups: n = 10 
per group. (j) PAS staining of kidney sections (4 days after treatment). For all groups, data are means ± SEM, 
*p < 0.05 vs control, #p < 0.05 vs cisplatin, Bar = 100 μm in (e,j) and = 50 μm in (h).
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We further examined whether additional treatment with pifithrin-α, a selective p53 inhibitor, can prevent 
the acceleration of cisplatin nephropathy by ATM inhibition. Pifithrin-α slightly improved the mortality rate of 
cisplatin nephropathy with ATM inhibition (Fig. 5h), although it did not improve renal function or renal histol-
ogy (Fig. 5i,j). These results suggested that pifithrin-α improved the repair process after severe renal injury by the 
co-administration of cisplatin and KU55933.
AtM inhibition reduced DnA repair. In response to cisplatin-induced DNA damage, several DNA repair 
pathways are activated and play essential roles in maintaining cell integrity and subsequent cell survival after 
injury. A previous report demonstrated the direct interaction of ATM and MutL homologue 1 (MLH1), which 
recognizes mismatched DNA and facilitates DNA mismatch repair (MMR)35–37, and was inhibited by KU5593338. 
Considering the negative regulatory effects on MMR of KU55933, we further analyzed its effects on the DNA 
repair process. Western blotting for MLH1 using isolated tdTomato+ tubular epithelia revealed that MLH1 
expression was not affected by either cisplatin or the co-administration of cisplatin and KU55933 (Fig. 6a,b). 
On immunostaining analysis of MLH1, nuclear MLH1+ cells were found in all experimental groups (Fig. 6c). 
Figure 6. DNA repair in the tubular epithelia is reduced in mice that received cisplatin and the ATM inhibitor. 
(a). Western blot of protein lysates from isolated tubular epithelia for MLH1 and GAPDH. Representative 
pictures of n = 2. Western blotting with n = 4 per group. (b) Optical density of MLH1 bands was normalized 
against that of GAPDH. (c) Immunostaining of kidney sections (2 days after treatment) for Mlh1 and (d) 
quantification of nuclear MLH1 + cells per high-power field. (e) qPCR of RNA from isolated tubular epithelia 
for the genes related to DNA repair. For all groups, data are means ± SEM, *p < 0.05 vs control, #p < 0.05 vs 
cisplatin, Bar = 50 μm in (c).
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Quantification analysis revealed that the number of MLH1+ cells was larger in the mice that received cisplatin, 
whereas there were fewer in the mice that received both cisplatin and KU55933 (Fig. 6d), suggesting that ATM 
inhibition slightly reduced MMR after cisplatin-induced tubular injury.
Regarding the other DNA repair pathways, we analyzed DNA repair-related gene expression in FACS-sorted 
tubular epithelia; parp1, parp2, xrcc1 and aptx for SSB repair, xrcc2 and xrcc3 for homologous recombination 
(HR), and fancd2 and bcra2 for the Fanconi anemia (FA) pathway (Fig. 6e). Although DNA damage was more 
marked in cisplatin- and KU55933-treated mice (Fig. 3l,m,n), expression of genes related to SSB repair and the 
FA pathway was similar to that in cisplatin-treated mice (Fig. 6e). Of note, xrcc1 expression was slightly reduced 
in cisplatin- and KU55933-treated mice. However, the expression of xrcc2 and xrcc3 for HR exhibited a signif-
icant increase in cisplatin- and KU55933-treated mice. Therefore, KU55933 inhibits the adaptive DNA repair 
processes, especially MMR and FA pathways, after cisplatin treatment in tubular epithelia.
Discussion
In order to elucidate the effects of ATM inhibition on injured proximal tubular epithelia, we administered 
KU55933 to mice with cisplatin-induced kidney injury and analyzed FACS-isolated proximal tubular epi-
thelia, which were exclusively labeled by cre recombinase-mediated reporter expression. There were 4 major 
findings in our study. First, ATM was phosphorylated in tubular epithelial cells after kidney injury and ATM 
inhibition accelerated cisplatin nephrotoxicity, thereby increasing mortality. Second, ATM inhibition exacerbated 
cisplatin-induced DNA damage in proximal tubular epithelia. Third, regardless of ATM inhibition, p53 and its 
downstream signaling pathways were activated, thereby inducing significant tubular apoptosis. Fourth, multiple 
DNA repair processes against cisplatin-induced DNA damage were attenuated by ATM inhibition, resulting in 
maladaptive DNA repair after cisplatin treatment. Taken together, these results suggest that ATM plays a protec-
tive role against DNA damage in cisplatin-induced tubular epithelial injury.
Our study demonstrated that ATM inhibition exacerbates cisplatin-induced DNA damage, eventually leading 
to a higher mortality. Regarding DNA damage and the subsequent pro-apoptotic response, ATM and ATR are 
phosphorylated, which induces cell cycle arrest, and DNA repair is facilitated via their downstream targets. p53 
is a major downstream molecule of ATM and is directly phosphorylated on serine 15 by pATM after DSB39. In 
our experiments, although immunostaining revealed a marked decrease in pATM expression in tubular epithelia 
by KU55933 treatment, the expression of tubular p53 and its downstream signaling paradoxically increased. 
p53 controls transcription-dependent and -independent mechanisms of downstream signaling. Low p53 expres-
sion results in the downregulation of cell cycle-related genes, such as p21, whereas higher expression induces 
pro-apoptotic responses such as PUMA expression40. PUMA, a strong regulator of the pro-apoptotic cascade 
through the mitochondrial pathway, accumulates in mitochondria, permeabilizes the mitochondrial membrane, 
and eventually induces mitochondrial injury8. Furthermore, cytoplasmic p53 itself accumulates in the mitochon-
drial matrix and induces mitochondrial injury41,42. These multifactorial pathways activated by ATM inhibition 
may have accelerated the mitochondrial injury and subsequent pro-apoptotic signaling observed in our study.
ATR, another central kinase involved in DDR, is activated by DNA SSB, whereas ATM is activated by DNA 
DSB43. Although these kinases are activated by different types of DNA damage, the downstream signaling 
responses partially overlap. Depletion of both ATR and ATM causes marked lethality following irradiation or 
administration of etoposide compared with the single depletion of ATR or ATM44. In addition, a recent study 
using mice with tubular epithelia specific deletion of ATR demonstrated that cisplatin-induced kidney injury 
was exacerbated and p53 was upregulated in mutant mice45, which is similar to our results of ATM inhibition. 
Considering these previous observations and our results of paradoxical p53 upregulation by KU55933, defects 
in ATR or ATM may be compensated by each other and upregulate p53. However, this compensatory effect was 
not sufficient to upregulate the DNA repair process, leading to the upregulation of pro-apoptotic signaling and 
exacerbated cisplatin-induced nephrotoxicity in vivo.
In response to non-severe cisplatin-induced DNA damage, DNA is repaired and cell death is prevented46. 
Cisplatin covalently binds to DNA bases and forms DNA adducts, blocking transcription and DNA synthesis47. There 
are two binding patterns between DNA and cisplatin, one is intrastrand adducts in which cisplatin binds to the same 
strand of DNA and the other is interstrand crosslink (ICL) in which cisplatin binds to the opposite strand of DNA. 
ICL occurs less frequently, less than 5% of total DNA platination, but it induces DSB, leading to severe DNA dam-
age47,48. Several DNA repair processes function against cisplatin-induced DNA damage, including MMR, nucleotide 
excision repair (NER), HR, nonhomologous end joining (NHEJ), translesion synthesis (TLS), and FA pathways49. As 
ATM and ATR recognize the site of DNA damage, these directly or indirectly activate different DNA repair pathways.
Regarding the MMR after tubular injury, our study demonstrated that the combination of cisplatin and KU55933 
slightly reduced nuclear MLH1 expression. Previous reports found that ATM is essential for stabilizing the complex 
of heterodimeric Mut, of which MLH1 is one of the major components35, and KU55933 decreased the association of 
these complexes38. In previous reports, the knockdown of MLH1 inhibited the DNA repair process50. Considering 
the significant expansion of DNA damage 2 days after cisplatin injection, reduced nuclear expression of MLH1 by 
KU55933 may inhibit the DNA repair process, thereby facilitating DNA damage and its downstream signaling.
Regarding the DNA repair process against ICLs, numerous pathways including NER, HR, and TLS, are 
required, and these are orchestrated by the FA pathway51,52. Of note, FANCD2, a central molecule of the FA 
pathway, is phosphorylated by ATM53,54. Although our comet study demonstrated that the frequency of DSB 
was not significantly different between cisplatin-treated mouse kidneys with or without KU55933, we com-
prehensively analyzed gene expression of molecules related to the FA and HR pathways. As a result, we found 
that cisplatin-induced activation of the FA pathway is attenuated by KU55933, HR pathways for xrcc2 and xrcc3 
expression were significantly upregulated in response to the acceleration of DNA damage by KU55933. In the case 
of cisplatin-induced ICL, both FA and HR pathways synergistically accelerated DSB repair, but our results suggest 
that ATM mainly involves the FA pathway rather than the HR pathway.
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Our study has several limitations. First, we found paradoxical upregulation of p53 in cisplatin- and 
KU55933-treated mouse kidney; however, the mechanism responsible for this upregulation is unclear. Considering 
the recent report demonstrating the similar upregulation of p53 in tubule-specific ATR knock-out mouse kidney45, 
and the compensatory interaction between ATR and ATM44, our results can be partially attributed to the upreg-
ulation of ATR, but future experiments are needed. Second, considering the paradoxical upregulation of p53 in 
cisplatin- and KU55933-treated mouse kidneys, we assumed that p53 was responsible for the exacerbation of 
kidney injury in our study. However, pifithrin-α did not ameliorate the severe renal histology of cisplatin- and 
KU55933-treated mouse kidneys, whereas it improved the mortality rate. Our results therefore cannot provide 
a reasonable explanation for this discrepancy, but another unknown pathway aside from p53-mediate apoptotic 
signaling may function in the development of severe renal histology. Third, unlike the cell-specific deletion of 
ATM, pharmacological inhibition of ATM may affect many cell types in the injured kidney. In a previous report, 
the cardioprotective effects of pharmacological ATM inhibition after doxorubicin treatment were attributed to its 
effects on interstitial fibroblasts rather than cardiomyocytes28. In contrast to such cardioprotective effects by phar-
macological inhibition of ATM, KU55933 significantly exacerbated the cisplatin-induced nephrotoxicity; however, 
the effects of ATM inhibition on other cell types, including fibroblasts or other inflammatory cells, remain unclear.
In conclusion, we identified a central role for ATM in the balance of DNA damage and repair in cisplatin 
nephropathy. Our study suggests that should future anticancer therapies combine cisplatin with an ATM inhib-
itor, the risks of AKI may increase. For any drugs that can induce DNA damage in renal tubular epithelia, com-
bination treatment with ATM inhibitors may accelerate tubular injury, thus careful monitoring of renal function 
or biomarkers should be required. In addition, as the mechanisms of the paradoxical upregulation of p53 under 
ATM inhibitor treatment have not been clarified, future experiments are required.
Methods
Animal experiments. We recently generated mice with the CreERT2 cassette in the SLC34a1 locus, which 
enables expression of the Cre recombinase in the proximal tubules after tamoxifen injection30. SLC34a1GCE mice 
were crossed with the R26tdTomato reporter mice in which tdTomato is expressed after Cre-mediated recom-
bination of the floxed stop cassette to obtain bigenic offspring. For genetic labeling, tamoxifen (Sigma-Aldrich 
Co., LCC., St. Louis, MO) was dissolved in 3% (vol/vol) ethanol containing corn oil (Sigma Aldrich Co., LCC., St. 
Louis, MO) at a concentration of 10 mg/ml. Tamoxifen was injected intraperitoneally at the indicated dose either 
once or every other day.
The cisplatin injury model was induced by intraperitoneal injection of cisplatin (Nippon Kayaku, Tokyo, 
Japan) in PBS at a concentration of 15 mg/kg body weight into mice at the age of 9-12 weeks. Mice were eutha-
nized 2, 4, or 14 days after the last cisplatin injection.
For ATM inhibition in vivo, 5 mg/kg of KU-55933 (ab120637, Abcam plc., Cambridge, UK) or vehicle (10% 
DMSO in saline) was intraperitoneally administered 30 minutes before, and 1, 2, 4, 7, and 14 days after cisplatin 
injection. For p53 inhibition in vivo, 2.2 mg/kg of pifithrin-α (ab120478, Abcam) was administered before cispla-
tin injection, and 2, 4, and 7 days after treatment. All experiments were approved by the Experimental Animals 
Committee, Kyoto Prefectural University of Medicine, and were performed in accordance with the institutional 
guidelines and Guidelines for Proper Conduct of Animal Experiments by the Science Council of Japan.
tissue preparation and histology. Mice were anesthetized and sacrificed, and kidneys were removed 
at the indicated time points. For frozen sections, kidneys were fixed with 4% paraformaldehyde (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan) for 1 h on ice, incubated in 30% (vol/vol) sucrose in PBS at 4 °C over-
night, and embedded in optimum cutting temperature compound (Sakura FineTek Japan co., Ltd., Tokyo, Japan) 
and cut into 7-μm sections.
For paraffin sections, the kidneys were fixed with 4% paraformaldehyde and embedded in paraffin by Applied 
Medical Research Laboratory (Osaka, Japan). Paraffin-embedded tissues were cut into 4-μm sections.
PAS and Masson’s trichrome staining was performed according to standard procedures. The kidney histology 
was examined on formalin sections stained with PAS and Masson’s trichrome. The degree of interstitial fibrosis or 
tubular injury was scored semi-quantitatively in five of 25 consecutive non-overlapping cortical fields of kidney 
sections stained with PAS and Masson’s trichrome under high magnification. Interstitial fibrosis was quantified 
using the following scores: 0, 0%; 1, 1–10%; 2, 11–25%; 3, 26–50%; 4, 51–75%; and 5, 76–100%. Tubular injury 
was judged by tubular atrophy, tubular dilation, protein casts, necrotic cells, and brush border loss13,55.
Immunofluorescence analysis. Sections were rehydrated and permeabilized with 0.5% Triton X-100 in 
PBS for 5 min. Samples were blocked with 10% normal goat serum in PBS and incubated with primary antibodies, 
as listed in Supplementary Table 1. Samples were then incubated with secondary antibodies, anti-rabbit or -rat 
Alexa Fluor 488-conjugate (Thermo Fisher Scientific, Waltham, MA), for 1 h. When the mouse antibody was used 
as the primary antibody, we used the Zenon Alexa Fluor 488 Mouse IgG1 Labeling Kit (Z25002: Thermo Fisher 
Scientific, Waltham, MA) in order to avoid cross-reactivity of the secondary antibody against the resident mouse 
IgG in the tissue. Nuclear counterstaining was performed using DAPI or DRAQ5 (DR50050; BioStatus; 1:1000), 
followed by mounting in Prolong-Gold (Thermo Fisher Scientific). Images were obtained by confocal microscopy 
(FV1000; Olympus, Tokyo, Japan). pATM+ tubular epithelia among tdTomato+ cells were quantified from five of 
25 consecutive non-overlapping cortical fields in each kidney under high magnification (n = 5). These five fields 
were randomly selected in a blinded manner.
immunohistochemistry and tUneL assay. After deparaffinization, paraffin sections were placed in 
citrate-buffered solution (pH 6.0) and boiled for 5 minutes to retrieve antigens. Endogenous peroxidase was 
quenched with 3.0% hydrogen peroxide in methanol for 20 minutes. Samples were blocked with 3% BSA in 
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PBS for 30 min at room temperature and incubated with primary antibodies (Supplementary Table 1). The sec-
tions were labeled with HRP-conjugated secondary antibodies, goat anti-rabbit (ab236469, abcam) or donkey 
anti-goat (sc-2020; Santa Cruz Biotechnology, Inc. Dallas, TX, USA; 1:500). Diaminobenzidine (DAB) chro-
mogenic substrate (K3468, Agilent Technologies, Inc., Santa Clara, CA) was used for the color reaction, fol-
lowed by counterstaining with hematoxylin. TUNEL staining for paraffin sections of the mouse kidney at 4 days 
after the treatments was performed using the ApopTag® Peroxidase In Situ Apoptosis Detection Kit (Merck 
S7100, Darmstadt, Germany) according to the manufacturer’s protocol. All sections were observed using the 
Eclipse E600 microscope (Nikon Corporation, Tokyo, Japan). pATM-, pATR-, γH2AX-, KIM-1-, MLH1-, and 
TUNEL-positive cells were quantified from five of 25 consecutive non-overlapping cortical fields in each kidney 
under high magnification (n = 5). These five fields were randomly selected in a blinded manner.
Separation of tdtomato-positive proximal tubular epithelia using fAcS. The kidney cortex was 
minced and a single-cell suspension was generated via research grade Liberase TL (5401020001:Sigma-Aldrich) 
and 60 units/ml of DNAse Inhibitor (D5025:Sigma-Aldrich) for 30 min at 37 °C.Cells were washed twice with 
PBS, filtered through 70- and 40-μm cell strainers, resuspended in PBS and 2%FBS with 1000:1 DAPI (1 mg/
mL), and subjected to FACS using SH800 (SONY). Dead cells (DAPI+) were excluded during FACS. TdTomato+ 
DAPI- cells were collected in DMEM and 10% FBS. RNA and protein were extracted using NucleoSpin® TriPrep 
(TAKARA Bio Inc, Shiga Japan).
RnA extraction and real-time quantitative pcR. Total RNA was isolated from the kidneys or 
FACS-sorted cells using TRIzol (Life Technologies, Inc., Carlsbad, CA) and Direct-zolTM RNA MiniPrep (Zymo 
Research Corporation., Irvine, CA) according to the manufacturer’s protocol. Subsequently, complementary DNA 
(cDNA) was generated using a Prime Script reverse transcription (RT) reagent kit (RR0471A Takara Bio Inc., 
Shiga, Japan), and real-time PCR was performed using KAPA SYBR Fast universal (KK4602: Kapa Biosystems, 
Wilmington, MA) and a Thermal Cycler Dice Real Time System (Takara Bio Inc., Shiga, Japan). All reactions 
were performed in duplicate. An initial denaturation step was performed for 10 min at 95 °C, and was followed by 
45 cycles of amplification at 95 °C for 10 s, 62 °C for 10 s, and 72 °C for 30 s. Gene expression was quantified using 
GAPDH as an internal control. The primers used are listed in Supplementary Table 2.
Western blot analysis. Total cell extracts were obtained using lysing buffer 17 (895943: R&D Systems, Inc. 
Minneapolis, MN, USA) for 5 min at room temperature. After sonication, proteins were denatured by heating 
for 5 min at 95 °C and separated by SDS-PAGE. Subsequently, proteins were transferred onto polyvinylidene 
difluoride (PVDF) membranes (Immobilon-P IPVH00010: Millipore, MA, USA). After blocking in 5% non-fat 
milk in TBS/0.1% Tween20 for 1 h at room temperature, the membrane was incubated with the correspond-
ing primary antibody (Supplementary Table 1) overnight at 4 °C. After washing with TBS/0.1% Tween20, sec-
ondary peroxidase-conjugated anti-mouse or anti-rabbit antibodies were added (7076S, 7074S; Cell Signaling 
Technology, Boston, MA; 1:3000 at room temperature). Chemiluminescence was detected using an ECL select 
Western blot detection reagent (RPN2235: GE Healthcare UK Ltd, Amersham Place, England) or Clarity Max 
western ECL substrate (1705062: Bio-Rad Laboratories, Inc. Hercules, CA, USA). Signal intensities were evalu-
ated using ImageJ software (National Institutes of Health, Bethesda, MD).
comet assay. The comet assay was performed using the Comet Assay Kit (abcam ab238544) according to the 
manufacturer’s protocol. In brief, mouse kidneys were removed and minced in a small amount of ice-cold PBS 
containing 20 mM EDTA. After removing the large pieces of tissue, the supernatant was passed through a 35-μm 
cell strainer. After centrifugation, the pellet was suspended at 1 × 105 cells/ml in ice-cold PBS. Cell samples were 
mixed with comet agarose in a 1/10 ratio (v/v) and immediately transferred onto the slide glasses covered with 
comet agarose base layer. After incubating with pre-chilled lysis buffer, the slides were subjected to electropho-
resis. Electrophoresis was performed in the Alkaline Electrophoresis Solution for the alkaline comet assay and 
in the TBE Electrophoresis Solution for the neutral comet assay. After electrophoresis, the slides were incubated 
with Vista Green DNA dye. Images were obtained by epifluorescence microscopy (IX71; Olympus, Tokyo, Japan) 
using the FITC filter. Ten pictures (5–15 cells per picture) were randomly taken, and the tail moment (tail length 
x tail % DNA/100) of 100 cells in the alkaline test and 50 cells in the neutral test per group was calculated using 
Comet Score analysis software (TriTek Corp.).
Statistics. Results are expressed as the mean ± SEM. Each experiment was performed using at least three 
mice per group. Statistical analysis was performed by the unpaired t-test for comparison of two variables, and by 
analysis of variance and Dunnett’s post hoc test for comparison of multiple variables. Survival curves after cispla-
tin treatment were analyzed by the Kaplan-Meier method and comparison of the two groups was performed using 
the Log rank test. P-values < 0.05 were considered significant.
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